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Abstract 
Prescription drug monitoring programs (PDMPs) are still in their infancy but have begun 
to demonstrate themselves as potentially useful tools to enhance safe and responsible prescribing 
of controlled substances. However, little is known about how Nurse Practitioners (NPs) use these 
programs and the potential barriers they face. The purpose of this project was to describe 
Alaskan Nurse Practitioner’s (NPs) current practice, beliefs, and barriers regarding the use of the 
Alaska PDMP. A questionnaire was sent to 635 Alaskan Advanced Nurse Practitioners and a 
total of 204 valid questionnaires were returned. The survey results provided data regarding 
prescribing habits, barriers to the use of the PDMP, and barriers registering for the PDMP, as 
well as opinions on items that could make the PDMP easier to use and more useful in clinical 
practice. It was found that more attention is needed to maximize its exposure and incorporation 
into daily workflow if it is to achieve its full potential for reducing drug misuse and abuse while 
increasing patient safety. Additional consideration should be given to authorizing registered 
users to delegate authority to a licensed person on their staff to access the PDMP in an attempt to 
reduce time commitments and increase its usage. Many providers felt that assigning each 
individual a unique patient identifier could prevent consumers from filling prescriptions under 
aliases or using multiple addresses, which undermines the effectiveness of the PDMP. Finally, an 
overwhelming majority of users want faster data entry and proactive reports. This project begins 
the exploration of the differences between PDMP users and nonusers and how NPs believe the 
process can be improved. A better understanding PDMP use will aide providers in safe 
prescribing practices while curbing the prescription drug epidemic and ultimately reducing 
abuse, misuse, and death from overdose. 
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 Prescription drug abuse has been declared the fastest growing drug problem in the U.S. 
(Paulozzi et al., 2012). Until the mid-1990s opioid pain relievers (OPRs) were reserved for the 
treatment of cancer pain (Reisman, Shenov, Atherly, & Flowers, 2009). In the late 1990’s and 
early 2000s there was a new movement to recognize the under treatment of pain (Garcia, 2013). 
Thus began an effort to recognize pain as the fifth vital sign, and a method for routine screening 
and assessment of pain was established (Garcia, 2013). The Joint Commission mandated pain as 
a vital sign and implemented the use of pain scores as a measure of patient satisfaction (Perrone, 
DeRoos, & Nelson, 2012). Concurrently, large organizations, such as the American Pain Society, 
published guidelines that called for aggressive treatment of any reported pain, and recommended 
an extension on the indication for OPRs to include treatment of chronic non-cancer pain (Keyes, 
Cerdá, Brady, Havens, & Galea, 2014; Perrone et al., 2012). The Department of Veterans Affairs 
also initiated a campaign aimed at improving pain management as well as treating chronic pain 
(Keyes et al., 2014). The combination of these actions served to further fuel the movement to 
aggressively treat pain with OPRs (Keyes et al., 2014). The threat of tort litigation for failure to 
treat or manage pain was used to encourage providers to comply and incentivize change (Garcia, 
2013).  
Over time, healthcare’s philosophy on the use of opioids for non-cancer pain shifted, and 
practitioners increased their rate of opioid prescriptions in an attempt to meet these new 
recommendations (Garcia, 2013; Paulozzi et al., 2012). In current practice, a patient’s subjective 
reports of pain may take precedence over other potentially competing considerations, such as 
addiction (Garcia, 2013). Despite their benevolent intentions, this new model created a scenario 
where prescribers including physicians, physician assistants, dentists, and nurse practitioners 
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(NPs), inadvertently joined drug cartels and street dealers as major players in the escalating drug 
use problem that America faces today (Perrone et al., 2012). 
 The United States consumes OPRs at a greater rate than any other nation in the world 
(Paulozzi, Mack, Hockenberry, 2014). Between 1999 and 2010 the sale of OPRs quadrupled, 
resulting in enough OPRs being prescribed to medicate every adult in America with 5mg of 
hydrocodone every 4 hours for a month (CDC, 2011). By 2012 37% of opioid users consumed an 
opioid stronger than morphine, 43% used a morphine equivalent strength opioid, and 20% used a 
weaker than morphine opioid (Frenk, Porter, & Paulozzi, 2015). This represents a 20% increase 
in patients that used a stronger than morphine opioid and 22% decline of patients that used a 
weaker than morphine opioid between 1999 and 2012 (Frenk et al., 2015). By 2013 almost 258.9 
million prescriptions for OPRs were written in the U.S., twice as many per capita than the second 
leading nation of Canada (Paulozzi et al., 2014).  
Prescription painkiller abuse is one of the fastest growing health problems in the United 
States today (Shepard et al., 2014). Between 1997 and 2003 there was a drastic increase in the 
yearly shipments of pain medications (Reisman et al., 2009). Oxycodone shipments increased 
479%, hydrocodone increased 148%, and morphine increased 100% (Reisman et al., 2009). 
Currently, the most dispensed pharmaceutical in the United States (U.S.) is 
hydrocodone/acetaminophen (e.g., Vicodin, Norco, Lortab), which accounts for nearly 137 
million prescriptions annually (Shepherd et al., 2014). While Americans are currently estimated 
to be approximately 4.6% of the world’s population, they consume nearly 80% of the global 
supply of OPRs (Wang & Christo, 2009). As a result, in the past year alone one out of every 
twenty Americans reported they had misused or abused prescription painkillers, and almost 
17,000 Americans died from prescription painkiller overdoses (Shepard et al., 2014). The 
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problem has become so invasive in our culture that the Center for Disease Control and 
Prevention (CDC) has classified prescription medication abuse as a health epidemic (Shepard et 
al., 2014).  
This phenomenon results in a high cost for the American economy. The U.S. Department 
of Health and Human Services estimates that prescription painkiller abuse costs the United States 
between $125 billion and $180 billion dollars annually (Shepard et al., 2014; Worley et al., 
2012). A 2006 breakdown of nonmedical OPR use and abuse costs found that this evolving 
problem accounted for $42 billion for lost productivity, $8.2 billion for criminal justice costs, 
$2.2 billion for drug abuse treatment, $944 million for medical complications, and $72.5 billion 
in direct healthcare costs for insurers annually (CDC, 2011; Shepard et al., 2014).  
Recently, a shift from focusing on the undertreatment of pain to addressing prescription 
drug morbidity and mortality has begun (Garcia, 2013). Various policies and regulatory 
approaches are being developed in an effort to combat this prescription drug abuse epidemic 
(Garcia, 2013). The pendulum has swung so far that there is now litigation in the opposite 
direction. A southern California physician has been charged with three counts of second degree 
murder in relation to the overdose deaths of her clients (Chakravarthy, Shah, & Lotfipour, 2012). 
She reportedly wrote 27,000 prescriptions for opiates and benzodiazepines over a three year 
period (Chakravarthy et al., 2012). If convicted she could receive up to a 45 year prison sentence 
(Chakravarthy et al., 2012).  
Prescription Drug Monitoring Programs (PDMPs) were developed by the law 
enforcement community to identify patterns of drug misuse, diversion, or excessive prescribing 
(Hildebran et al., 2014). These PDMPs are increasingly gaining recognition in the healthcare 
community as a tool that can aid providers in identifying patients who are at risk of harm from 
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prescription drug abuse, as well as helping to identify potential sources of drug diversion 
(Hildebran et al., 2014). The White House Office of National Drug Control Policy, the CDC, and 
the Food and Drug Administration have realized the potential of these programs and are 
currently suggesting that state-based PDMPs be expanded (Perrone & Nelson, 2012). While the 
potential benefits of PDMPs are beginning to be realized, they remain underutilized due to 
inadequate funding, variable levels of functionality, and inconsistent use (Perrone et al., 2012). 
Thus far there is very little knowledge about clinicians’ experiences with, perceptions of, or 
attitudes toward PDMP systems (Hildebran et al., 2014). Additional information about how 
clinicians integrate the state’s PDMP into their daily clinical workflow could help identify “best 
practices” regarding PDMPs and help guide their development in ways that best suit prescribers’ 
needs (Hildebran et al., 2014). Little research has explored how APRNs are using PDMPs, how 
the information impacts patient care and diversion, and if APRNs think PDMPs are easy to use 
and add value to their practice (LeMire, Martner, & Rising, 2012). 
Relevance to Alaska Advanced Nurse Practitioners 
 Prescription drug abuse has been noted to be more concentrated in states that have a high 
number of individuals living in rural communities, such as Kentucky, West Virginia, Alaska, and 
Oklahoma (Keyes et al., 2014). Many counties outside of urban regions have been found to have 
higher rates of overdoses related to OPRs, higher injury rates related to OPRs, and higher ratios 
of nonmedical to medical users of OPRs (Keyes et al., 2014). In addition, adolescents in rural 
communities have been found more likely to abuse OPRs recreationally when compared to their 
metropolitan counterparts (Keyes et al., 2014). These are concerning facts given most of Alaska 
is considered rural.  
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 There are several unique factors associated with increased OPR consumption in rural 
regions. It has been well documented that geographical poverty and unemployment increases the 
occurrence of drug abuse in an area (Keyes et al., 2014). Large scale economic downturns affect 
rural areas of the U.S. more severely, resulting in widespread unemployment and increased 
poverty (Keyes et al., 2014). Areas that have a mining and heavy labor as the predominate 
industry have been shown to dispense far greater amounts of prescription narcotics in an effort to 
maintain a functional workforce (Keyes et al., 2014). This is closely related to the evidence that 
chronic pain and injury are more prevalent in rural regions (Keyes et al., 2014).  
There is growing evidence that many misused OPRs are obtained from family, friends, or 
acquaintances who originally obtained the medication through legitimate channels (Keyes et al., 
2014). Since family structures in rural areas are larger and tend to develop wider networks, there 
are potentially a greater number of avenues available to secure illicit narcotics (Keyes et al., 
2014). All of these factors combine to create a situation where high prescription rates result in 
increased availability of OPRs in these regions (Keyes et al., 2014). 
 Alaska ranked 26th in the purchases of Oxycodone products in 2011, but ranks 47th in 
total population (Office of National Drug Control Policy, 2011). In 2008 Alaska ranked 5th in 
the nation with 18.1 drug overdose deaths per 100,000 population (CDC, 2011). Of particular 
relevance was that the highest rates of overdose deaths in 2008 was seen in non-Hispanics and 
American Indians/ Alaska Natives, nearly three times greater than Hispanics and blacks 
(Chakravarthy et al., 2012).  
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Purpose 
The purpose of this project was to describe Alaskan NPs current practice regarding the 
Alaska Prescription Drug Monitoring Program, and to identify barriers that may prevent or 
reduce the use of the program. 
Literature Review 
History of the Prescription Drug Monitoring Program 
 PDMPs were originally implemented by law enforcement agencies in an attempt to 
identify patterns of diversion, misuse, and over prescribing (Hildebran et al., 2014). Over time 
the PDMPs have become valuable tools for improving health care in communities and helping 
providers identify patients at risk of harm secondary to addiction or unsafe medication practices 
(Hildebran et al., 2014). As of December 2013, there were operational PDMPs in 48 states and 
the territory of Guam (Finklea, Sacco, & Bagalman, 2014). New Hampshire and the District of 
Columbia had legislation on the books but were yet to have operational programs, while 
Missouri was still attempting to pass legislation related to PDMPs (Finklea et al., 2014). That 
same year the Obama Administration presented the 2013 Prescription Drug Abuse Prevention 
Plan, which includes the monitoring of controlled substances with PDMPs as one of four major 
focuses (Gershman, Fass, & Popovici, 2014). 
 The average cost to implement a PDMP is $350,000, and the average annual operating 
expense is $500,000 (Finklea et al., 2014). In reality the annual operating costs are between 
$125,000 and $1 million, and depend on the size of the state, number of registered users, and the 
complexity of the PDMP program (University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy, 2010). One variable related to expense is whether the system is reactive or 
proactive (Finklea et al., 2014). Most states have a reactive system that only provides data to 
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practitioners who log into the database and request information on an individual (Worley et al., 
2012). Proactive systems are more complex and notify providers and pharmacies when a patient 
exceeds specified thresholds for concerns of doctor shopping, which is defined as visiting 
multiple physicians to obtain multiple prescriptions for illegal use or abuse (Worley et al., 2012). 
While proactive programs are more expensive, they have been shown to have a more substantial 
impact on diversion (Worley et al., 2012). 
 PDMPs can be invaluable tools in the effort to track consumers’ usage of controlled 
substances, monitor geographical trends of use, and assist law enforcement in their efforts. Some 
PDMPs report in real time, but these programs are expensive to operate. As such, most PDMPs 
have some delay in reporting and are best used to evaluate an individual’s prescription patterns 
over time, as opposed to looking for recent transactions in the preceding week (Baehren et al., 
2010). At present, Alaska requires that pharmacies report to the PDMP by the 5th of the 
following month (B. Howes, personal communication, January 15, 2015). Accessing the PDMP 
can inform a provider if the patient has utilized several different providers for OPRs, raising the 
suspicion that the patient may be engaging in doctor shopping, or visiting multiple providers to 
obtain multiple prescriptions (Islam & McRae, 2014). At the same time, the prescriber may 
identify a patient who has a legitimate need for pain medications, but is at risk of complications 
from polypharmacy due to multiple providers attempting to assist the patient with pain 
management (Islam et al., 2014). Also, accessing the PDMP may provide a certain level of 
comfort that the patient is adhering to a pain management contract, allowing the provider to 
forgo urine screening in effort to develop or enhance the patient-provider relationship (Islam et 
al., 2014). Having an awareness of the PDMP may provide an incentive for the patients to be 
forthright with their history, also helping foster open communication during the visit (Islam et 
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al., 2014). Data suggests that OPR overdoses often occur in high dose users who seek treatment 
from multiple providers, and accessing the database can help practitioners to intervene in a 
timely fashion by identifying the pattern earlier (Islam et al., 2014; Paulozzi et al., 2012). Lastly, 
some clinicians utilize the PDMP to ensure there are no false prescriptions under their name, and 
to coordinate care with other providers when there is a concern (Hildebran et al., 2014). 
 On a larger scale, the PDMP can be utilized to identify geographical areas that have the 
highest rates of misuse so that focused interventions can be aimed at these communities (Islam et 
al., 2014). For example, death rates secondary to OPRs varied from 1.8 to 15.6 per 100,000, with 
rural and impoverished counties having higher rates of overdose death (CDC, 2011). These areas 
of concern can be identified and unique interventions specific to that region can be implemented. 
States also have the authority to track and regulate medical practices in their area, and the 
information gleaned from the PDMP can help determine factors driving high prescribing rates 
and guide regulations to curb the growth of OPR prescribing (Paulozzi et al., 2014). These 
governing agencies can then use the PDMP to track the effects of their interventions (Paulozzi et 
al., 2014). For example, New York and Tennessee mandated provider use of the PDMP and then 
used the PDMP to reveal respectively a 75% and 36% decline in multiple prescribers (Paulozzi 
et al., 2014).  
 Since the PDMPs were originated by law enforcement agencies it is no surprise they 
continue to utilize them in their investigations. Some areas of focus for law enforcement include 
targeting providers who overprescribe controlled substance for drug dealers and abusers, 
pursuing pharmacies that falsify documentation, and identifying individuals that forge 
prescriptions (Finklea et al., 2014). In 2010, 3% of physicians were responsible for prescribing 
62% of all OPRs dispensed (CDC, 2011). In the same year 90 of the top 100 oxycodone 
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prescribing physicians were found to be practicing in Florida (Islam et al., 2014). Using PDMP 
data to identify patterns of prescribing, law enforcement agencies reduced the number of over 
prescribers in Florida to thirteen (Islam et al., 2014). 
 The Alaska PDMP is run by the Alaska Board of Pharmacy and became operational in 
2012, it currently costs between $65,000- $70,000 annually to operate (B. Howes, personal 
communication, January 15, 2015). All schedule II- V drugs dispensed are reported to the PDMP 
by 5th of every month, and query generated reports include all of these scheduled drugs 
dispensed over the previous two years (B. Howes, personal communication, January 15, 2015). 
Twenty-one states have enacted legislation requiring out of state, mail order, and Internet 
pharmacies to report medications dispensed to residents to the state PDMP and Alaska is one of 
them (Finklea et al., 2014). Despite the lack of advertisement, there are currently approximately 
13,000 providers enrolled in the program (B. Howes, personal communication, January 15, 
2015). No information is available on the number of active users or the number of times 
providers access the system in a given time period.  
 At present, federally funded programs, such as Indian Health Services (IHS), Department 
of Defense (DOD), and the Department of Veteran Affairs (VA), are exempted from reporting to 
the PDMP in the state in which they are located (Hildebran et al., 2014). One of the goals of the 
Executive office is to encourage these facilities to report all controlled substance prescriptions 
that are dispensed to the PDMPs of the states in which they operate (Executive Office, 2011). 
There will also be recommendations that encourage the DOD, VA, and IHS to develop and 
implement standards for having providers review the PDMP prior to generating a prescription for 
narcotics (Executive Office, 2011). The IHS healthcare community in Alaska has already begun 
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the process of reporting to the PDMP, but JBER and VA pharmacies still do not (B. Howes, 
personal communication, January 15, 2015). 
America’s Youth 
 A particularly alarming trend is developing in America’s youth, where the use of 
medications for nonmedicinal purposes has become a serious problem in high school and college 
populations (Shepherd, 2014; Wang et al., 2009). The 2010 Monitoring the Future study 
discovered that six of the top ten substances used by high school seniors were prescription 
medications (Office of National Drug Control Policy, 2011). At that time nearly 12 million 
children age 12 or older reported the use of prescription pain killers for nonmedical reasons 
within the last year (Garcia, 2013). In 2011, 61% of young adults surveyed admitted to using 
OPRs or stimulants at some point in their lifetime (Lord, Brevard, & Budman, 2011). Amongst 
high school and college aged individuals pharmaceuticals are now third, behind marijuana and 
alcohol, in terms of substance use (Strogner, Sanders, & Miller, 2014). Unfortunately, 
adolescents perceive OPRs as more harmful than other prescription drugs but less harmful than 
almost all other drugs, except experimental alcohol and marijuana use (Keyes et al., 2014).  
 The decrease in the availability of illicit narcotics and increase in supply of OPRs has 
shifted public demand and has generated a street market. While the home prescription cabinet 
remains a source for narcotics, drug dealers are becoming a more popular source for OPRs for 
adolescents (Inciardi, Surratt, Cicero, & Beard, 2009). In a study of Delaware 11th graders, over 
70% admitted to obtaining prescription drugs from street dealers (Inciardi et al., 2009). Another 
study looking at 10 to 18 year olds in Detroit public schools noted the most common avenue of 
obtaining prescription drugs was through a street level drug dealer (Boyd, McCabe, & Teter, 
2006). There is also emerging data that indicates a portion of college students use a dealer to 
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obtain their prescription drugs (Rigg, Kurtz, & Surratt, 2012). Some experts contend that the war 
on drugs has resulted in tighter control of street drugs, leading more teenagers to turn to 
prescription medications (Wang et al., 2009). 
Increase in Opiate Related Overdoses 
 There has been such an increase in the death rates from OPRs that it has been declared an 
epidemic in the U. S. (CDC, 2011). Since 2003 there have been more overdose deaths related to 
OPRs than heroin and cocaine combined (Paulozzi, 2012). In 2007, there were a reported 27,000 
unintentional drug overdose deaths in the U.S. (Paulozzi et al., 2012). By 2008 there were 36,450 
deaths related to OPR, nearing the leading cause of injury death in the U.S., which was motor 
vehicle collisions at 39,973 (CDC, 2011). For every overdose death there are several other less 
lethal encounters with OPR abusers, such as nine admissions for substance abuse treatment, 35 
emergency room (E.R.) visits, and 161 reports of drug abuse/ dependence (Paulozzi et al., 2012).  
Of particular importance to the healthcare provider is the fact that nearly all of the OPRs 
involved in overdose deaths were originally prescribed by a provider (Finklea et al., 2014). It has 
been found that long acting and extended release OPRs are more prone to abuse and deserve 
special attention as high dose formulations of these medications are far more likely to result in 
overdose (Paulozzi et al., 2014). Also, benzodiazepine and OPRs, when taken in combination, 
increase the risk for overdose, yet these are commonly prescribed together by some providers 
(Paulozzi et al., 2014). 
A Growing Concern for Women 
The increase in E.R. visits is possibly related to the fact that women are more likely to be 
prescribed OPRs than men, receive higher doses of OPRs, and use them chronically (CDC, 
2013). This has led to an increase in the death rate from OPRs amongst women. Between 1999 
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and 2010, there has been a fivefold increase in the number of deaths in women that were 
attributed to OPRs (CDC, 2013). While men continue to have a greater total number of deaths 
from overdose, the overall percentage of increase in women is greater (CDC, 2013). In 2007, 
more women died from drug overdose each year than from the leading cause of avoidable injury, 
motor vehicle collisions. Additionally, since 2010 four times as many women died from 
overdose than were victims of homicide (CDC, 2013). The highest rates of death from overdose 
have been noted in ages 45 to 54 years old with 21.8 per 100,000 populations (CDC, 2013). 
Increase in Deception and Diversion 
 The DEA has estimated that diversion is a $25 billion a year industry (Rigg et al., 2012). 
The term ‘disorganized crime’ is used by many to describe the mysterious complexity of the 
prescription medication diversion problem in society today (Rigg et al., 2012). Drug diversion 
involves the removal of drugs from legal marketplaces and distributing them in illegal ones 
(Gugelmann, Perrone, & Nelson, 2012). This includes the distribution of drugs to friends or 
family, as well as the sale, theft, and forgery of prescriptions, prescription pads, and Drug 
Enforcement Agency (DEA) numbers (Gugelmann et al., 2012).  
 Diversion of pharmaceuticals can take on many forms. Some common techniques for 
obtaining OPRs were pain clinic shopping, buying prescriptions, sponsoring, and using an inside 
‘connect’ (Rigg et al., 2012). From a provider standpoint, the primary methods to obtain drugs 
for diversion are doctor shopping, manipulation or deception of providers, and stolen or forged 
prescriptions (Baehren et al., 2010). The Department of Justice confirmed this in a report to the 
Government Accountability Office (GAO) when they stated that doctor shopping is the primary 
manner in which individuals obtain OPRs for illegitimate use (U.S GAO, 2013). After obtaining 
a prescription, some patients will reserve a portion of their drugs with the intent to sell, give 
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away, or use for recreational purposes (Stogner et al., 2014). Some 76% of recreational OPR 
users reported receiving their drugs from their friends, family, drug dealers, or strangers 
(Paulozzi et al., 2012). An additional 20% of users stated they acquired OPRs from their own 
doctor or from more than one provider (Griggs, Weiner, & Feldman, 2015).  
 While some diversion is small and may go undetected, there are some impressive 
examples in the literature. In a report to the GAO it was noted that 600 Medicare patients had 
received prescriptions from 21 to 87 different practitioners, leading the organization to conclude 
that the patients were supporting an addiction or diverting medications (U.S. GAO, 2013). A 
more specific example involved a beneficiary in Maryland who received a total of 5923 
oxycodone tablets, a 1,450 day supply, from 11 different prescribers (U.S. GAO, 2013). One 
physician caring for the patient reported that the beneficiary had a pain management contract 
stating that he would only receive narcotics from their sole provider (U.S. GAO, 2013).  
 Women are a particular subgroup of doctor shoppers, as they are more likely to engage in 
doctor shopping than men (CDC, 2013). Women were noted to employ elaborate measures to 
elude identification and deceive the system (Worley & Thomas, 2014). To negate the providers’ 
attempts to detect abuse they worked together sharing pills for pill counts, trading urine for 
routine drug screening, and exchanging x-rays or MRIs (Worley et al., 2014). Some went as far 
as sponsoring others and providing rides to and from appointments (Worley et al., 2014). The 
women also discussed manipulating providers as they attempted to con them into writing 
prescriptions for the medications they sought (Worley et al., 2014). To bait a practitioner the 
women would exaggerate or fabricate symptoms such as pain and anxiety while denying the fact 
that another provider had provided them with prescriptions previously (Worley et al., 2014). In 
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many instances the women were successful doctor shoppers because the provider failed to take 
even the simplest measure to prevent it, such as checking the state’s PDMP (Worley et al., 2014).  
Opposing Viewpoint 
Some are concerned of the potential for chilling effects or substitution effects. The 
chilling effect refers to the reluctance of some providers to prescribe controlled substances due to 
fear of retribution (Goodin, Blumenschein, Freeman, & Talbert, 2012). High profile criminal 
prosecutions can inhibit a practitioner from prescribing OPRs, as it causes concern they will be 
the target of scrutiny from law enforcement or their licensing bodies (Finklea et al., 2014; 
Goodin et al., 2012). The substitution effect is prescribing alternative, non-controlled 
medications, even if they have inferior effectiveness or a greater side effect profile (Islam et al., 
2014). This was seen when only schedule II medications were being recorded and there was a 
temporary increase in hydrocodone prescriptions (Paulozzi, Kilbourne, & Desai, 2011). This can 
be dangerous as many of these formulations contain acetaminophen and increase the potential of 
hepatic failure resulting from acetaminophen poisoning (Paulozzi et al., 2011). However, abuse 
of OPRs is a major public health issue and these concerns can be largely mitigated if clear, 
concise standards of practice are adhered to. Furthermore, the first response to questionable 
practices should be undertaken by governing healthcare bodies prior to being passed on to law 
enforcement agencies (Islam et al., 2014). A 2009 study found that while there was an 
improvement in outcomes after the implementation of the PDMP, there continued to be a 
significant rise in OPR shipments between dispelling the notion that PDMPs have a chilling 
effect on prescribing practices (Reisman et al., 2009). 
 Initially these programs may consume more of a provider’s already scarce time (Islam et 
al., 2014). Taking additional time to review the PDMP may increase wait times and negatively 
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influence the patients rating of their visit (Hildebran et al., 2014). Providers are also concerned 
that utilizing the PDMP may result in decreased patient satisfaction scores. When a provider is 
concerned for abuse there should be subsequent questioning, counseling, and possible referral for 
treatment, all consuming more of the practitioners time (Islam et al., 204). Prescribers who opt to 
not prescribe OPRs secondary to concerns for abuse are faced with another scenario in which 
they are likely to have increased dissatisfaction scores (Hildebran et al., 2014). This is significant 
because negative scores can have a serious impact on a provider’s reimbursement and job 
security (Islam et al., 2014). For most ethical providers these concerns would be largely 
outweighed by a desire to provide high quality healthcare and prevent negative long term health 
consequences in their clientele.  
PDMP Effectiveness 
 Thus far the theoretical benefits of PDMPs have been well cataloged but scarcely studied 
(Gugelmann et al., 2012). Research that focused on the PDMPs effects on OPR abuse that were 
completed prior to 2008 had mixed results (Griggs et al., 2015). During that time period PDMP 
databases were primarily utilized by narcotic control agencies to assist in identification and 
investigation of those engaged in illegal activities, not as healthcare resources (Guoha, Brady, 
Lang, Giglo, Wunsch, & DiMaggio, 2014). Several unique data collection points made it 
difficult to compare state to state. Some of these confounding factors included the schedules of 
medications that were reported, who was required to report data, how often the data was 
submitted, who was allowed access to the database, and whether there was interstate sharing of 
information (Garcia, 2013). PDMP programs were also less advanced at that time. Eight of the 
PDMPs that were studied stated that reports were made available within one hour of request, 
thereby limiting the providers’ ability to make an intervention at the time of presentation (Wang 
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et al., 2009). Results related to overdose deaths were also influenced by who recorded the data 
during the death investigation. In states where deaths from injury were investigated by a medical 
examiner there was a significantly higher report of overdose mortality when compared to the 
states that utilized coroners (Guoha et al., 2014). Finally, most of the studies did not distinguish 
between proactive and reactive programs (Finklea et al., 2014).  
 Even today there is limited research relating to the effectiveness of PDMPs (Finklea et 
al., 2014). However, there are factors that have been attributed to this lack of effectiveness of 
PDMPs on overdose mortality. Foremost is the markedly limited use of PDMPs by all providers 
mainly due to real and perceived barriers related to access (Guoha et al., 2014). Inadequate 
provider training and lack of incentives have resulted in decreased buy-in from prescribers 
(Guoha et al., 2014). A lack of interstate sharing can result in a provider only seeing a limited 
view of a patient’s prescription history, especially in border towns (Guoha et al., 2014). 
Surprisingly, only 22 of the states currently require a customer to present photo identification 
prior to receiving a scheduled medication, thereby allowing doctor shoppers to elude detection 
(Griggs et al., 2015). However, since their inception PDMPs have made substantial technological 
advances and developed into Internet based platforms thereby surmounting many these historical 
hurdles (Perrone et al., 2012). 
 Evidence that PDMPs are making a difference is beginning to emerge. In 2009, PDMP 
states were found to have a lower per capita shipment of oxycodone, a lower percent increase in 
opioid related admissions, and a lower ratio of patients entering treatment for OPRs (Reisman et 
al., 2009). Not only did PDMP states have a lower incidence of admissions related to OPRs, but 
the gap continued to widen with each successive year studied (Reisman et al., 2009). 
Furthermore, eight of the ten states with the highest number of OxyContin prescriptions did not 
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have PDMPs, while six of the ten lowest states had implemented PDMPs (Office of National 
Drug Control Policy, 2011). In 2012, the Researched Abuse, Diversion and Addiction-Related 
Surveillance (RADARS) System, Poison Control Center, and Opioid Treatment Programs voiced 
their agreement that PDMPs have been shown to decrease OPR misuse in the general population 
(Reifler et al., 2012). In the most recent data available from the CDC, overdose deaths related to 
OPRs fell 5% between 2011 and 2012, marking the first decrease in over a decade (Griggs et al., 
2015).  
 PDMPs can also influence a provider’s prescribing patterns. Interestingly, 91% of the 
physicians who accessed the PDMP did so because of concern for prescription drug abuse 
(Gershman et al., 2014). Of those that accessed the system, 93.6% of physicians reported the 
information gleaned influenced the type or quantity of the medication that was ultimately 
prescribed (Gershman et al., 2014). This resulted in nearly 68% of the physicians switching to a 
nonscheduled pain reliever, while another 30% were less concerned about prescribing OPRs 
after reviewing the PDMP (Gershman et al., 2014). A study of medical toxicologists, who 
primary work in E.R.s, were found to have a more equitable split with nearly equal numbers of 
OPR prescriptions changing in both directions (Perrone et al., 2012). Another study of ER 
providers found that reviewing the PDMP resulted in a relatively small number of changes, but 
changes occurred in both directions with more than twice as many patients receiving a 
prescription that was not previously planned (Weiner et al., 2013). Another study of Ohio 
providers found that OPR prescribing changed in 41% of the cases after the PDMP was reviewed 
(Baehren et al., 2010). Of those cases, 61% received fewer OPRs than was originally intended 
and 39% received more pain medication than was originally planned (Baehren et al., 2010). 
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Significance to Nurse Practitioners 
  As primary care providers, NPs are at the front line of a growing prescription drug abuse 
problem. In many states, NPs have a wide scope of practice and manage patients independently; 
as a result they prescribe a similar number of controlled substances as their counterparts in the 
primary care arena (Cipher, Hooker, & Guerra, 2006). NPs are also similar to other providers in 
the frequency at which they prescribe controlled substances; while physicians prescribed a 
controlled substance 12.4% of the time, physician assistants wrote narcotic prescriptions 12.3% 
of the time, and NPs did so in 11% of their visits (Cipher et al., 2006). As providers, NPs have 
legal and ethical obligations to identify individuals at risk and intervene in an effort to promote 
patient safety and be responsible prescribers (Worley et al., 2014). Therefore, PDMPs may be 
beneficial to help identify potential problems in their practice (LeMire et al., 2012). Furthermore, 
the PDMP provides the NP with an opportunity to intervene early during the initial stages of a 
potential problem, while the patient is still in the clinical setting (Perrone et al., 2012).  
The use of PDMPs is becoming more prevalent in the evidence-based practice for pain 
management literature. American Family Physicians Journal recommends that providers, 
including nurse practitioners, check the PDMP during the decision making phase of prescribing 
OPRs, and that ongoing monitoring should include regular surveillance of data from the state 
PDMP (Berland & Rodgers, 2012). The Institute for Clinical Systems Improvement encourages 
prescribers to routinely use tools, including the use of a centralized database, to identify and 
monitor usage in patients that are receiving scheduled medications (Hooten et al., 2013). Finally, 
the American Academy of Pain Medicine recommends that monitoring compliance with chronic 
opioids prescriptions should include random urine drug screening, pill counts, and periodic 
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review of prescription monitoring data base reports (American Academy of Pain Medicine, 
2013). 
Purpose Statement and Research Questions 
The purpose of this project is to identify the barriers that may prevent Alaskan NPs from 
utilizing the PDMP as well as barriers to enrolling in the PDMP for nonusers. This data will 
serve as a starting point for understanding the barriers Alaska NPs face in regards to PDMP 
enrollment and use. Ideally, this will allow the Alaska PDMP to implement targeted education, 
thus decreasing barriers and increasing use of the program amongst Alaska NPs. The following 
research questions will be addressed:  
1. Who are the primary users and nonusers of the PDMP? 
2. What are the prescribing patterns of users and nonusers? 
3. What are the perceived barriers to use in regards to the Alaska PDMP? 
4. What are the perceived barriers to enrollment by nonusers? 
5. What would make the PDMP easier to use? 
6. What would make the PDMP more useful in daily practice? 
Methods 
Design 
 This project was performed using a quantitative descriptive design. An eleven question 
survey was used for data collection: the first question established prior knowledge of the PDMP, 
followed by five multiple choice Likert scale questions with open-ended space for additional 
comments, and finally five questions regarding demographics made up the questionnaire. The 
final questionnaire used in this study required less than 10 minutes to complete. 
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Instrument 
 The original surveys were developed by Jessica M. Irvine, Sarah E. Hallvik, Christi 
Hildebran, Miguel Marino, Todd Beran, and Richard A. Deyo (Irvine, 2014). The authors of the 
survey developed the questionnaire based on current gaps in the literature, input from state 
program experts, clinical experts, an earlier and smaller state survey, and focus groups with 
clinicians from nine other states who were active users of their states' PDMPs (Irvine, 2014). 
There was no mention of reliability testing and only a description of content validity by the 
original authors of the questionnaire. The principal author’s permission to use the questionnaire 
and modify as needed was received via email conversation (Appendix C). 
 Minor changes were made to the survey in order to adapt the survey to NPs practicing in 
Alaska. Additional questions were added asking NPs to score their thoughts regarding loss of 
business and poor satisfaction scores being seen as a barrier to PDMP use. An additional 
demographic question was added asking providers if they practiced in urban, rural road, or rural 
off road environments which are specifics related to living and practicing in Alaska. Additional 
minor modifications to the questionnaire were made following recommendation from committee 
members and University of Alaska School of Nursing faculty.  
Sampling 
The intended sampling frame included exclusively Advanced Nurse Practitioners 
practicing in Alaska. First, the professional license database was downloaded from the State of 
Alaska Department of Commerce, Community, and Economic Development website. Since the 
aim of this study was to look at Nurse Practitioners who work in Alaska, and therefore may use 
the Alaska PDMP, all out of state addresses were eliminated from the mailing list. Ultimately, 
635 clinicians were eligible to participate in this study.  
   
 
29 
 
A preemptive postcard was mailed on January 13, 2016 two weeks prior to the 
questionnaire mailing in an attempt to raise awareness and improve the response rate. The author 
then prepared hand addressed envelopes, also in an attempt to increase return rates. Included in 
the mailing was an introduction letter that explained the survey and the implied consent, as well 
as a self-addressed, stamped envelope for the return of the survey. The author then mailed the 
surveys on January 25, 2016. Data was collected over a three- week period and resulted in 204 
questionnaires being included in the analysis.  
Rights and Protection of Human Subjects 
 The Institutional Review Board (IRB) at the University of Alaska Anchorage approved 
the project. A cover letter explaining the project to potential respondents was included with 
every mailing (Appendix A). Clinicians gave their consent to participate in the study by 
completing and returning the survey. There was no identifying information on the surveys other 
than basic demographic information. All questionnaires and data files were only available to the 
principal investigator, committee chair, and committee member. The anonymous paper 
questionnaires were saved in a locked filing cabinet and the compiled data was saved on a 
password protected external hard drive secured in the same locked filing cabinet. 
Results 
Analysis 
 Analysis of the data was performed using SPSS version 23 in order to complete 
demographic statistics. All responses were converted to a numeric score for data entry. Answers 
to the open-ended questions were entered into SPSS as they were written by the respondent, and 
were analyzed to identify any recurring themes within the responses by using inductive content 
analysis as described by Elo and Kyngas (2007). Respondents were asked demographic 
   
 
30 
 
questions in regards to age, gender, years practicing as a NP, specialty of practice, and practice 
setting. Demographic information regarding years of practice was collected via an open-ended 
question and was later grouped into five year categories which resulted in eight groups. The 
respondents’ area of practice was also combined into categories to facilitate comparisons and 
resulted in: Family Practice, Women’s Health, Midwifery/ OBGYN, Mental Health/ Psychiatry, 
Pediatrics, Specialty Clinic, and Other groupings. Where appropriate, chi-square tests were used 
to determine statistical differences between groups. 
Respondents 
A total of 635 questionnaires were mailed, after removing 32 questionnaires that were 
returned as undeliverable the total number of potential respondents was 603. A total of 217 
surveys were returned. Six of these surveys were excluded because the ANPs stated they were 
retired, and therefore did not complete the survey in its entirety. An additional seven surveys 
were excluded because the majority of the survey was incomplete and there was no demographic 
information. This left 204 valid surveys for a 33.8% response rate. 
The vast majority of respondents were female (95.1%, n = 194), while 4.4% were male 
(n = 9), and one respondent did not list a gender (Table 1). The majority of respondents were 
ages 50 to 59 years (34.8%, n = 71), followed by age 60 years or older (29.4%, n = 60), ages 30 
to 39 years (17.6%, n = 36), ages 40 to 49 years (15.7%, n = 32), and under age 30 years (2.5%, 
n = 5). After the specialty of practice category was combined, most respondents listed 
themselves as Family Practice 46.1% (n = 94), followed by 17.6% (n = 36) declaring their 
primary employment as a Specialty Clinic. Other specialties were: Women’s Health, 10.8% (n = 
22); Mental Health/ Psychiatry, 10.8% (n = 22); Midwifery/ OBGYN, 5.4% (n = 11), other 5.4% 
(n = 11); and Pediatrics, 4% (n = 8). Years of experience as a NP ranged from 1 to 40 years. 
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After combining years of experience into five year groups the most frequent responses were 0 to 
5 years 22.1% (n = 45) along with 16 to 20 years 22.1% (n = 45). Regarding location of practice, 
urban providers represented the majority (64.2%, n = 131), while 26.5% (n = 54) reported their 
area of practice as rural, and only 8.8% reported a rural location off the road system (n = 18). 
The Alaska Board of Nursing does not consider demographic information public record, so the 
age and gender mix of nurse practitioner respondents may not be demographically representative 
of the Alaska NP population.  
Table 1. 
 Demographic Characteristics of Respondents According to PDMP User Status 
Demographic All Respondents n (%) 
Registered Users 
n (%) 
Nonusers 
n (%) 
 204 (100) 98 (48) 106 (52) 
Age category    
<30 5 (2.5) 2 (2) 3 (2.8) 
30 to 39 36 (17.6) 16 (16.3) 20 (18.9) 
40 to 49 32 (15.7) 21 (21.4) 11 (10.4) 
50 to 59 71 (34.8) 30 (30.6) 41 (38.7) 
≥60 60 (29.4) 29 (29.6) 31 (29.2) 
Gender    
Female 194 (95.1) 93 (94.9) 101 (95.2) 
Male 9 (4.4) 5 (5.1) 4 (3.8) 
Years of practice    
0 to 5 45 (22.1) 20 (20.4) 25 (23.6) 
6 to 10 34 (16.7) 15 (15.3) 19 (17.9) 
11 to 15 38 (18.6) 24 (24.5) 14 (13.2) 
16 to 20 45 (22.1) 23 (23.5)  22 (20.8) 
21 to 25 12 (5.9) 3 (3.1) 9 (8.5) 
26 to 30 12 (5.9) 3 (3.1) 9 (8.5) 
31 to 35 11 (5.4) 7 (7.1) 4 (3.8) 
36 to 40 5 (2.5) 2 (2) 3 (2.8) 
Specialty of practice    
Family Practice 94 (46.1) 56 (57.1) 38 (35.8) 
Specialty Clinic   36 (17.6) 20 (20.4) 16 (15.1) 
Women’s health 22 (10.8) 3 (3.1) 19 (17.9) 
Mental Health/ Psychiatry 22 (10.8) 14 (14.1) 8 (7.5) 
Midwifery/ OBGYN 11 (5.4) 2 (2) 9 (8.5) 
Pediatrics 8 (3.9) 0  8 (7.5) 
Other 11 (5.4) 3 (3.1) 8 (7.5) 
Area of practice    
Urban 131 (64.2) 64 (65.3) 67 (63.2) 
Rural 54 (26.5) 16 (16.3) 28 (26.4) 
Rural off road 18 (8.8) 8 (8.2) 10 (9.4) 
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Comparison of Registered Users versus Nonusers 
Demographics 
Age. When comparing users to nonusers, respondents ages 40 to 49 years were 31.2% 
more likely to be enrolled in the PDMP (Figure 1). A chi-square test of independence was 
performed to examine the relation between user status and age. The relation between these 
variables was not significant, X2 (4, N = 204) = 5.235, p=.264. There was no significant 
difference when comparing groups based on age. 
 
Figure 1. Age of respondents by user status. 
Gender. A chi-square test of independence was performed to examine the relation 
between user status and age. The relation between these variables was not significant, X2 (1, N = 
203) = .200, p=.655. There was no significant difference when comparing groups based on 
gender. 
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Years practicing as a Nurse Practitioner. Respondents with 11 to 15 years of 
experience were 26.4% more likely to be enrolled in the PDMP (Figure 2). Also of note was that 
NPs with 31 to 35 years of experience were 29.2% more likely to be users of the PDMP, while 
NPs with 21 to 25 and 26 to 30 years of experience were 50% more likely to not be enrolled in 
the program. However, all groups with 21 years of experience or greater had 12 or less 
respondents. A chi-square test of independence was performed to examine the relation between 
user status and years of experience as a NP. The relation between these variables was not 
significant, X2 (7, N = 202) = 10.398, p=.167. There was no significant difference when 
comparing groups based on years of experience. 
 
Figure 2. Years of experience of respondents by user status. 
Specialty. Family Practice and Mental Health/ Psychiatry were heavily represented in the 
user group in this survey (Figure 3). In contrast, Pediatrics, Women’s Health, and Midwifery/ 
OBGYN were more heavily represented in the nonuser group of the survey. No practitioners 
practicing in pediatrics reported being enrolled in the PDMP (0%, n = 8). Prior to combining 
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specialty of practice into categories it was noted that 100% (n = 6) of pain management NPs 
reported being enrolled in the program. Also, there were relatively few respondents who 
practiced in the inpatient environment. A chi-square test of independence was performed to 
examine the relation between user status and specialty of practice. The relation between these 
variables was significant, X2 (6, N = 204) = 31.626, p=<.001. There was a significant difference 
when comparing groups based on specialty of practice.  
 
Figure 3. Specialty of practice by user status 
Predominant area of practice. A chi-square test of independence was performed to 
examine the relation between user status and area of practice, which was defined as urban, rural, 
or rural off road. The relation between these variables was not significant, X2 (2, N = 203) = .124, 
p=.940. There was no significant difference when comparing groups based on area of practice. 
Prescribing Patterns  
 Registered NPs reported prescribing all classes of controlled substances more often than 
nonusers (Table 2). However, many of the non-registered NPs also reported frequently 
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prescribing controlled substances. Among the 106 nonusers in this study, 49.1% (n = 52) 
reported occasionally (1–5 times per week) or frequently (5 or more times per week) prescribing 
any class of controlled substance. A chi-square test of independence was performed to examine 
the relation between user status and prescribing habits. The relation between user status and each 
variable was significant, signifying that there was a significant difference when comparing 
groups. 
Table 2.  
Prescribing Habits According to PDMP User Status 
Class of Controlled Substance 
PDMP 
Registered Users 
n (%) 
Nonusers 
n (%) p value 
Prescribe opioids at least weekly 58 (59.2) 33 (31.1)  <.001 
Prescribe benzodiazepines at least weekly 56 (57.1) 29 (27.4) <.001 
Prescribe amphetamine-like drugs at least 
weekly 
39 (39.8) 16 (15.1) <.001 
Prescribe sleep medications at least 
weekly 
60 (61.2) 26 (24.5) <.001 
 
Barriers to Use by Registered Users 
Registered users were provided with a list of concerns and asked to check which and to 
what extent each was a barrier to using the PDMP (Table 3). The NP’s who were enrolled in the 
PDMP identified time constraints as the largest barrier to use with 66% (n = 64) finding it to be a 
somewhat or a significant barrier. Being unable to designate someone to access the system on the 
registrants’ behalf had a mixed response, with 49.5% (n = 48) finding it to be a somewhat or a 
significant barrier. Enrolling in the program was also seen as a barrier by many, as the 
cumbersome registration process was cited as a somewhat or a significant barrier by 42.3% (n = 
41). Areas that were not identified as a barrier to use or only rarely a barrier included: concerns 
related to loss of business (99%, n = 96), concerns related to poor patient satisfaction scores 
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(99%. n = 96), comfort using a computer or internet (96.9%, n = 94), concerns related to 
scrutiny by professional licensing board (95.9%, n = 93), concerns related to scrutiny by law 
enforcement (93.8%, n = 91), and lack of training (71.1%, n = 69).  
 In the free text area provided for respondents to enter other barriers, seven cited concerns 
with passwords, the password reset process, and password retrieval. Four individuals took the 
time to praise the system or state that there were no barriers. Finally, two other individuals 
remarked that it was not connected to their electronic health record (EHR), and this causes them 
lost time and difficulty researching a client as they are forced to navigate between two different 
programs. 
Table 3.  
Barriers to Use of the Alaska PDMP by Registered Users 
Barrier to Use by Registered Users Somewhat- Significant barrier 
Not- 
Rarely a 
 barrier 
Time constraints to access PDMP during patient 
visits 64 (66.0) 33 (34) 
I cannot designate someone to access the system on 
my behalf 48 (49.5) 46 (50.5) 
Cumbersome registration process 41 (42.3) 56 (57.7) 
Lack of training on how to access or use the PDMP 28 (28.9) 69 (71.1) 
Concerns about scrutiny by law enforcement 6 (6.2) 91 (93.8) 
Concerns about scrutiny by professional licensing 
board  4 (4.1) 93 (95.9) 
Concerns related to poor patient satisfaction scores 3 (3.1) 94 (96.9) 
Not comfortable using computer or Internet 1 (1) 96 (99) 
Concerns for loss of business 1 (1) 96 (99) 
 
Reasons Nonusers Have Yet to Register 
 There were a total of 106 Nonregistered individuals and 38 (35.8%) of this subgroup had 
never heard of the PDMP prior to receiving the questionnaire. Additionally, a full 55.7% (n = 
59) of unregistered users were not aware that they could register (Table 4). A nearly equally 
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large percentage, 44.3% (n = 47), cited the reason for not registering was that they rarely 
prescribed controlled substances. In contrast, areas that were less cited as barriers to registering 
were: No Internet at work (3.8%, n = 4), object to surveillance (3.8%, n = 4), limited resources 
to do anything with the information (3.8%, n = 4), not allowed to share with staff (4.7%, n = 5), 
don’t think there would be any benefit (11.3%, n = 12), and too busy (24.5%, n = 26). 
 In the free text area provided for respondents to enter other barriers, nine federal 
employees (Military and Indian Health Services) stated that they did not believe their computer 
systems would allow them to access an outside vendor or assumed that the pharmacist would 
provide surveillance. Five respondents were inpatient providers or serviced long term care or 
incarcerated clients and didn’t feel that the PDMP would influence their prescribing patterns. 
Only one provider stated that she prescribed exclusively to their long term clients and that they 
knew them well enough to not be concerned. 
Table 4.  
Barriers to Registering for the Alaska PDMP by Non-Registered Users 
Barrier to Registering Rate n (%) 
I’m not aware that I could register as a user 59 (55.7) 
I rarely, if ever, prescribe controlled substances 47 (44.3) 
I’m too busy 26 (24.5) 
I don’t think there would be any benefits 12 (11.3) 
I’m not allowed to share the account with my support staff 5 (4.7) 
There is no Internet access at work 4 (3.8) 
I ethically and/or morally object to surveillance of patient medication 
habits / prescriptions 4 (3.8) 
Limited funds/resources to do anything with the information returned 
(e.g., referral to substance abuse treatment) 4 (3.8) 
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Improving the Alaska PDMP 
Making the PDMP Easier to Use 
 All participants were asked what would make the PDMP easier to use (Table 5). The 
most common response by all users was that they wanted to have generated reports sent to them 
when someone they prescribe for is suspected of misuse or diversion (64.2%, n = 131), but 
72.4% (n = 71) of the user subgroup requested this change (p=.018). The majority felt that 
authorizing someone else to access the system on their behalf (50.5%, n = 103) would make the 
system easier to use. However, the user subgroup selected this option more frequently (61.2%, n 
= 60) compared to the nonuser subgroup (40.6%, n = 43) (p=.003). 
 User groups also differed in their desire to receive training on how to use the system, 
while 56.6% (n = 60) of all respondents declared a desire for training on the use of the system, 
only 31.6% (n = 31) of the user subgroup felt they needed training (p=<.001). Considering that 
time constraints were cited as an area of concern by both groups, surprisingly only 44.1% (n = 
90) declared they thought training on how to incorporate accessing the PDMP into daily 
workflow would make the PDMP easier to use. 
Table 5.  
What Would Make the PDMP Easier to Use 
 
All 
respondents 
n (%) 
Users 
n (%) 
Nonusers 
n (%) 
p 
value 
Having the state send reports to me 
automatically when patient patterns suggest 
potential misuse or diversion 
131 (64.2) 71 (72.4) 60 (56.6) .018 
Ability to authorize someone else to access 
system on my behalf 103 (50.5) 60 (61.2) 43 (40.6) .003 
Training on how to use the system 91 (44.6) 31 (31.6) 60 (56.6) <.001 
Training on how to incorporate PDMP into 
clinical workflow 
90 (44.1) 45 (45.9) 45 (42.5) .618 
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Making the PDMP More Useful in Clinical Practice 
All providers were asked what would make the PDMP more useful in clinical practice 
(Table 6). At least 72% (n = 147) of clinicians thought that faster entry and display of 
prescriptions in a database would be somewhat or very useful. When looking at subgroups, 
90.8% (n = 89) of users found this topic to be somewhat or very useful, whereas only 45.3% (n 
= 48) of non-users found it useful (p=<.001). User groups also differed when it came to their 
opinions on the usefulness of unique patient identifiers (p=<.001) and linking state PDMP 
systems (p=<.001). Respondents in both groups agreed that it would be somewhat or very useful 
to: receive training on resources that are available within the community 61.3% (n = 125) and 
receive training on communicating findings in a non- confrontational manner (52.5%, n = 107).  
Table 6.  
What Would Make the PDMP More Useful in Clinical Practice? 
 All respondents n (%) 
Users 
n (%) 
Nonusers 
n (%) 
p 
value 
Faster entry and display of prescriptions 
in database 
147 (72.1) 89 (90.8) 58 (54.7) <.001 
Linking state PDMP systems 136 (66.7) 81 (82.7) 55 (51.9) <.001 
Unique patient identifier to avoid 
mistaken identity or use of aliases 
129 (63.2) 74 (75.5) 55 (51.9) <.001 
Training on how to respond to PDMP 
information/ resources available 125 (61.3) 69 (70.4) 56 (52.8) .010 
Training to communicate PDMP findings 
in non-confrontational manner 107 (52.5) 51 (52) 56 (52.8) .910 
Training on how to interpret the data 103 (50.5) 45 (45.9) 58 (54.7) .209 
 
Discussion 
 Among survey respondents, there was no significant difference between the PDMP users 
and nonusers in regards to age, gender, years of practice, or location of practice. There was a 
statistically significant difference amongst the two groups when compared by specialty of 
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practice. The PDMP appeared to be widely used by clinicians from many disciplines, especially 
those from Family Practice, Mental Health/ Psychiatry, and Pain Management. While Pediatric 
and Women’s Health NPs were predominately nonusers of the program. No Pediatrics NPs in 
this survey were registered users, but also reported never prescribing opioids, benzodiazepines, 
or sleep aides and only occasionally prescribing amphetamine like medications. This pattern was 
seen in other specialties, as respondents who were not registered users of the PDMP were 
infrequent prescribers of controlled substances compared to their counterparts. However, nearly 
half of all nonusers reported prescribing at least one class of controlled substance weekly. 
Raising concerns that providers may underestimate the amount of controlled substances they 
prescribe.  
 Time constraints were the most commonly cited barrier to using the PDMP by those that 
are currently registered users. This was followed closely by not being able to designate someone 
to access the system on the provider’s behalf, perhaps allowing a licensed staff member to access 
the PDMP would decrease the clinician’s time burden and increase the use of the program. While 
not listed as a choice, many providers wrote in that they had difficulty with the password portion 
of the PDMP, and felt that an online retrieval system for a forgotten password would be 
beneficial.  
Over half of all of nonusers reported that they were not aware they could register for the 
PDMP, indicating a need to increase education on the program. However, registered users found 
the registration process to be cumbersome and could indicate another area of improvement that 
could occur prior to attempting to recruit nonusers. Increased recruitment efforts may not be 
hugely successful, given that nearly half of unregistered providers feel that they rarely prescribe 
controlled substances. Amongst those who have yet to enroll in the PDMP, over half felt that 
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training on use of the system would improve the process, indicating that education on program 
usage is warranted for new users. A particular subgroup that could be targeted is NPs in the 
federal government systems, as they erroneously believe that the governmental computer 
systems will not allow them to access an outside vendor’s program or that the pharmacist will 
provide oversight on their behalf.  
Providers from both groups indicated a desire to have proactive reports sent to them 
whenever they prescribed medications to a patient with a pattern that is concerning for misuse or 
diversion. This may indicate that providers wish to have the information, but that time 
constraints may prevent them from investigating every patient. Clinicians also felt that faster 
entry and display of prescriptions would make the PDMP more useful in clinical practice.  
Strengths and Limitations 
 Important strengths of the study include its statewide sampling, inclusion of PDMP 
nonusers, and identification of respondents' specialties. Few of the previous studies have 
addressed nonusers of the PDMP or identified respondents’ specialty of practice. Additionally, 
this is the first survey of NPs in Alaska in regards to PDMP usage. 
Several limitations of the study were identified. The survey used was not tested for 
reliability and was only tested for content validity. The survey response rate was suboptimal, and 
a low response rate has the potential of introducing a bias, as respondents may systematically 
differ from non-respondents in their demographics, clinical characteristics, or perceived barriers. 
As always, results from one state’s population may not be generalizable to clinician populations 
in other states. Several specialty groups contained small sample sizes thereby making specialty 
comparisons difficult. As in any survey, social influences may create a bias, although this bias 
was potentially reduced by providing anonymity to the respondents. 
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Conclusions and Recommendations 
 Prescription drug monitoring programs are relatively new developments that can aide 
providers in delivering high quality care while helping to maintain safety and oversight. With 
The White House Office of National Drug Control Policy, the Centers for Disease Control and 
Prevention, and the Food and Drug Administration calling for an expansion of state-based 
PDMPs, these programs appear to be here to stay (Perrone et al., 2012). However, 
underutilization of these programs will continue to negate the potential benefits of these 
programs rendering them ineffective in the fight to reduce prescription drug misuse. Some states 
have recognized this as a problem, and as of October 2014, 22 states have passed legislation 
requiring that prescribers review the PDMP in certain scenarios (Griggs et al., 2015). While 
PDMPs are not a panacea for OPR misuse, they are a valuable tool available to practitioners as 
an attempt to curb the over prescribing of these drugs. 
Now that the Alaska PDMP is well established, more attention is needed to maximize its 
exposure and incorporation into daily workflow if it is to achieve its full potential for reducing 
drug misuse and abuse while increasing patient safety. Future research should focus on 
identifying optimal strategies for reaching clinicians that are unaware of the existence of the 
PDMP or are unaware that they are eligible to enroll in the program. Additional consideration 
should be given to authorizing registered users to delegate authority to a licensed person on their 
staff to access the PDMP in an attempt to reduce time commitments and increase its usage. Steps 
should be taken to brief federal government employees on the program and encourage providers 
to take back responsibility for investigating their patients scheduled medication consumption 
patterns. In an attempt to provide new users with desired training, a brief video tutorial could be 
made available on the PDMP website detailing the basic usage of the program. Many providers 
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felt that assigning each individual a unique patient identifier could prevent consumers from 
filling prescriptions under aliases or using multiple addresses, which undermines the 
effectiveness of the PDMP. While an overwhelming majority of users want faster data entry and 
proactive reports, this could substantially raise the cost of the program and further study would 
be needed to evaluate the cost benefit ratio.  
Dissemination Plan 
An application for poster presentation at the Alaska NP Conference in September of 2016 
was submitted for review. A copy of this project will be sent to Brian Howes at the Alaska 
PDMP for review and consideration. As this is currently a wide conversation in the news and 
medical literature I will attempt to have the results published in The Journal for Nurse 
Practitioners, the official publication of the American Association of Nurse Practitioners.  
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Appendix A 
Cover Letter 
Alaska Nurse Practitioners Barriers of Use of Prescription Drug Monitoring Program 
 
Researchers: 
Heath Christianson, RN    Elizabeth Driscoll, PhD, FNP, RN  
Graduate Student, UAA School of Nursing  Faculty, UAA School of Nursing 
(907) 570-4353     (907) 786-4594 
 
Description: 
You are being asked to participate in a survey to explore barriers to the use of the State of Alaska’s 
Prescription Drug Monitoring Program.  You have been chosen to participate in this study because you 
have an active Alaska Nurse Practitioner license.  Your name and address was obtained from public 
records available through the State of Alaska Department of Commerce, Community, and Economic 
Development. 
 
Voluntary Nature of Participation: 
Your participation in this project is voluntary.  If you agree to participate, you may choose not to answer 
any given questions, and you may discontinue your participation at any time prior to returning the 
completed survey.  Your informed consent is implied upon completion and return of the questionnaire.   
 
Confidentiality: 
Your responses to the survey will be confidential.  Since all responses are intended to be anonymous, 
please do not write your name or address anywhere on the questionnaire or return envelope.  Aggregated 
results will be stored in a computer with password protection, and deleted at the conclusion of this study.  
Returned paper copies of the survey will be stored in a locked file cabinet for three years, then destroyed.   
 
Potential Benefits and Risks:  
The questionnaire should take 5- 10 minutes to complete. In this project, there are no known economic, 
legal, physical, psychological, or social risks to participants in either immediate or long-range outcomes.   
 
Compensation: 
There is no compensation for your participation in this study.  The results of the survey will be presented 
at Alaska Nurse Practitioner conference and the Alaska Board of Pharmacy. 
  
Contacts:  
If you have any questions about this project or the results please contact me, Heath Christianson; 
hchristianson@alaska.edu; 907-570-4353, or Dr. Elizabeth Driscoll; emdriscoll@uaa.alaska.edu; 907-
786-4594, at the Department of Nursing, University of Alaska Anchorage. If you have any concerns about 
your participation in this study, please contact the UAA Research Integrity & Compliance Officer, (907) 
786-1099.  
 
Thank you for your time and cooperation. 
 
Sincerely, 
 
Heath Christianson 
Elizabeth Driscoll 
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Appendix B 
Questionnaire 
Prescription Drug Monitoring Programs in Clinical Practice: A Survey of Alaskan Nurse 
Practitioners 
 
 
1. Have you heard about the Prescription Drug Monitoring Program, also known as PDMP?  
   Yes 
   No  
 
2. How often do you prescribe the following classes 
of drugs for your patients? 
Never 
I do rarely 
(1/month) 
I do occasionally 
(1‒5/week) 
I do frequently 
(5+/week) 
Opioids  ?   ?   ?   ?  
Benzodiazepines  ?   ?   ?   ?  
Amphetamine‐like drugs  ?   ?   ?   ?  
Sleep medications  ?   ?   ?   ?  
 
3. If you are a registered user, to what extent are the following a 
barrier to your use of the PDMP? 
Not a 
barrier 
Rarely a
 barrier 
Somewhat 
a barrier 
Significant
barrier 
Lack of training on how to access or use the PDMP ?   ?   ?   ?  
Concerns about scrutiny by law enforcement  ?   ?   ?   ?  
Concerns about scrutiny by professional licensing board  ?   ?   ?   ?  
Time constraints to access PDMP during patient visits ?   ?   ?   ?  
I cannot designate someone to access the system on my behalf ?   ?   ?   ?  
Cumbersome registration process  ?   ?   ?   ?  
Not comfortable using computer or Internet  ?   ?   ?   ?  
Concerns for loss of business  ?   ?   ?   ?  
Concerns related to poor patient satisfaction scores ?   ?   ?   ?  
List other barriers here: 
 
 
 
 
 
4. If you are not registered as a user, which of the following describe the reason you have not registered? (check all that apply)
I’m not aware that I could register as a user  ?  
There is no Internet access at work  ?  
I’m too busy  ?  
I don’t think there would be any benefits  ?  
I’m not allowed to share the account with my support staff ?  
I rarely, if ever, prescribe controlled substances ?  
I ethically and/or morally object to surveillance of patient medication habits / prescriptions ?  
Limited funds/resources to do anything with the information returned (e.g., referral to substance abuse 
treatment) 
?  
Other reason (please specify):  
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5. What would make the PDMP easier to use? 
Training on how to use the system  ?  
Training on how to incorporate PDMP into clinical workflow  ?  
Ability to authorize someone else to access system on my behalf (e.g., Medical Assistant)  ?  
Having the state send reports to me automatically when patient patterns suggest potential misuse 
or diversion 
?  
Other (please specify): 
 
 
 
 
 
 
6. What would make the PDMP more useful to you in clinical practice? 
Not 
useful 
Somewhat 
useful 
Very useful 
Training on how to interpret the data  ? ?  ?
Training to communicate PDMP findings in non‐confrontational manner  ? ?  ?
Training on how to respond to PDMP information (e.g., resources for 
managing addiction problems; other resources within my community) 
?  ?  ? 
Faster entry and display of prescriptions in database (currently up to one 
month lag) 
?  ?  ? 
Unique patient identifier to avoid mistaken identity or use of aliases  ? ?  ?
Linking state PDMP systems (i.e., Washington, California)  ? ?  ?
Other (please specify): 
 
 
 
 
 
 
7. What is your age?   ?  Under 30  ?  30‒39       ?  40‒49        ?  50‒59       ?  60 or older 
 
8. What is your gender?     ?  Female  ?  Male 
 
9. How many years have you practiced as a Nurse Practitioner? __________________ 
10. How would you categorize your area of practice (i.e., Family practice, Surgery)? ______________________ 
 
11. How would you classify the area in which you practice? 
? Urban   ?   Rural   ?   Rural off road 
 
 
 
Thank you for taking the time to complete this questionnaire. 
 
For more information or to enroll in the Alaska PDMP please go to: http://www.alaskapdmp.com/ 
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Appendix C 
Email Correspondence with Principal Author Jessica M. Irvine 
 
Heath Christianson <hmchristianson@gmail.com> Wed, Dec 31, 2014 at 11:11 AM
To: jirvine@acumentra.org 
Good morning and Happy New Year, 
 
I am nearing completion of my Family Nurse practitioner degree at The University of Alaska 
Anchorage. As part of the degree requirements I am attempting to complete a project related to how 
NPs in Alaska use our PDMP. During my literature I found your questionnaire to be the best fit. I am 
writing to request permission to use your questionnaire in my research project. Please feel free to 
contact me if you have any additional questions. 
  
Cheers, 
Heath Christianson 
907-570-4353 
 
 Jessica Irvine <JIrvine@acumentra.org> Wed, Dec 31, 2014 at 11:20 AM
To: Heath Christianson <hmchristianson@gmail.com> 
Hello Heath, 
 Yes‐ please do use the questionnaire in your project. I’m glad it will be useful for you. Please let me 
know if you have any questions. 
 Thank you and Happy New Year! 
Jessica 
  Jessica Morea Irvine, M.S.Research ManagerAcumentra Health 
2020 SW 4th Ave, Suite 520Portland, OR 97201 503.382.3946971.409.6110 
 503.382.3997jirvine@acumentra.org  http://www.acumentra.org/PDMP/ 
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From: Heath Christianson [mailto:hmchristianson@gmail.com]  
Sent: Wednesday, December 31, 2014 12:12 PM 
To: Jessica Irvine 
Subject: PDMP questionnaire 
[Quoted text hidden] 
IMPORTANT NOTE: The information contained in this message may be privileged, confidential, and 
protected from disclosure. If the reader of this message is not the intended recipient, or an employee 
or agent responsible for delivering this message to the intended recipient, you are hereby notified that 
any dissemination, distribution, or copying of this communication is strictly prohibited. If you have 
received this communication in error, please notify us immediately and delete this message from your 
computer. Acumentra Health. 
 
 Heath Christianson <hmchristianson@gmail.com> Wed, Dec 31, 2014 at 11:26 AM
To: Jessica Irvine <JIrvine@acumentra.org> 
Thank you for the quick response.  I will email you if any questions arise. If I get any interesting 
findings I'll send them your way. 
  
